J Korean Rheum Assoc.  2007 Jun;14(2):105-111. 10.4078/jkra.2007.14.2.105.

Guidelines for Prevention of Tuberculosis in Patients with Rheumatoid Arthritis Treated with TNF-alpha Blockers

• Kwok SK
• Park SH

• KMID: 1526426
• DOI: http://doi.org/10.4078/jkra.2007.14.2.105

Abstract

Introduction
of tumor necrosis factor (TNF) inhibitor for the treatment of rheumatoid arthritis (RA) induces not only significant improvement of symptoms and signs of RA but also substantial inhibition of progressive joint damage. Such therapeutic efficacies of TNF inhibitor have led to a paradigm shift in the treatment of RA. In spite of its dramatic effect against RA, it is now well established that the use of TNF inhibitor significantly increases the risk of tuberculosis in patients with RA. Therefore some countries have presented guidelines in the use of TNF inhibitors for rheumatoid arthritis to reduce the risk of tuberculosis. Korea Food and Drug Association (KFDA) have also provided guidelines for treating latent tuberculosis when using TNF inhibitors. In this article, we reviewed the general epidemiology of tuberculosis and incidence rates of tuberculosis in RA patients and those of RA patients treated with TNF inhibitors. We also introduced methods for the diagnosis of latent tuberculosis, and various guidelines published in different countries in managing tuberculosis in RA patients who were to be treated with TNF inhibitors. Finally, we suggest requirement of more appropriate guidelines for Korean RA patients who are candidates for treatment with TNF-inhibitors.

Keyword

Rheumatoid arthritis; TNF inhibitor; Tuberculosis

MeSH Terms

Arthritis, Rheumatoid*
Diagnosis
Epidemiology
Humans
Incidence
Joints
Korea
Latent Tuberculosis
Tuberculosis*
Tumor Necrosis Factor-alpha*
Tumor Necrosis Factor-alpha

Reference

1). Feldmann M., Brennan FM., Maini RN. Rheumatoid arthritis. Cell. 1996. 85:307–10.

2). Asquith DLL., McInnes IB. Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheumatol. 2007. 19:246–51.

3). McInnes IB., Liew FY. Cytokine networks–towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2005. 1:31–9.

4). Saxne T., Palladino MA Jr., Heinegard D., Talal N., Wollheim FA. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 1988. 31:1041–5.

5). 송정수. 류마티스관절염치료에서종양괴사인자억제제사용에대한고찰. 대한류마티스학회지. 2007. 14:1–14.

6). Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am. 2004. 30:237–55.

7). Imperato AK., Bingham CO 3rd., Abramson SB. Overview of benefit/risk of biological agents. Clin Exp Rheumatol. 2004. 22((5 Suppl 35):):S108–14.

8). Jasmer RM., Nahid P., Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med. 2002. 347:1860–6.

9). Tufariello JM., Chan J., Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis. 2003. 3:578–90.

10). Mohan VP., Scanga CA., Yu K., Scott HM., Tanaka KE., Tsang E, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun. 2001. 69:1847–55.

11). Keane J., Gershon S., Wise RP., Mirabile-Levens E., Kasznica J., Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001. 345:1098–104.

12). British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax. 2005. 60:800–5.

13). Miyasaka N., Takeuchi T., Eguchi K. Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol. 2005. 15:4–8.

14). Miyasaka N., Takeuchi T., Eguchi K. Guidelines for the proper use of etanercept in Japan. Mod Rheumatol. 2006. 16:63–7.

15). Mariette X., Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis. 2003. 62:791–2.

16). Elkayam O., Balbir-Gurman A., Lidgi M., Rahav G., Weiler-Ravel D. Guidelines of the Israeli association of rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers. Harefuah. 2007. 146:235–7. ,244.

17). TNF 길항제사용시잠복결핵치료지침. 식품의약품안전청2004.

18). Mazurek GH., LoBue PA., Daley CL., Bernardo J., Lardizabal AA., Bishai WR, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA. 2001. 286:1740–7.

19). Ferrara G., D'Amico R., Losi M. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet. 2006. 367:1328–34.

20). Pai M., Riley LW., Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004. 4:761–76.

21). Kang YA., Lee HW., Yoon HI., Cho B., Han SK., Shim YS, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA. 2005. 293:2756–61.

22). Lee JY., Choi HJ., Park IN., Hong SB., Oh YM., Lim CM, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J. 2006. 28:24–30.

23). 2007년세계결핵의날보도자료. 보건복지부.

24). 2007년결핵관리지침. 질병관리본부: 대한결핵협회결핵연구원.

25). 심태선: 고원중: 임재준: 류우진. 국내에서잠복결핵의진단및치료. 결핵및호흡기질환. 2004. 57:101–17.

26). Bouza E., Moya JG., Munoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am. 2001. 15:335–61.

27). Yun JE., Lee SW., Kim TH., Jun JB., Jung S., Bae SC, et al. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol. 2002. 20:127–32.

28). Kang I., Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol. 2003. 15:528–34.

29). Mok MY., Lo Y., Chan TM., Wong WS., Lau CS. Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. J Rheumatol. 2005. 32:609–15.

30). 김충현: 김완욱: 양철우: 정영옥: 도주호: 고혁재등. 전신성홍반성루푸스환자와신장이식환자에서발생한결핵의임상적특징비교. 대한류마티스학회지. 2003. 10:270–7.

31). Kim HA., Yoo CD., Baek HJ., Lee EB., Ahn C., Han JS, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol. 1998. 16:9–13.

32). Seong SS., Choi CB., Woo JH., Bae KW., Joung CL., Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007. 34:706–11.

33). Brassard P., Kezouh A., Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006. 43:717–22.

34). Carmona L., Hernandez-Garcia C., Vadillo C., Pato E., Balsa A., Gonzalez-Alvaro I, et al. EMECAR Study Group. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol. 2003. 30:1436–9.

35). Askling J., Fored CM., Brandt L., Baecklund E., Bertilsson L., Coster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005. 52:1986–92.

36). Wolfe F., Michaud K., Anderson J., Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004. 50:372–9.

37). Gomez-Reino JJ., Carmona L., Valverde VR., Mola EM., Montero MD. BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003. 48:2122–7.

38). 허지안: 서수홍: 박성환: 조철수: 김호연. 류마티스관절염환자에서잠복결핵진단을위한투베르클린검사와T-SPOT.Γβ 사이의일치율에관한연구. 대한류마티스학회지. 2006. 13:285–90.

39). Munoz P., Rodriguez C., Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis. 2005. 40:581–7.

40). Benito N., Sued O., Moreno A., Horcajada JP., Gonzalez J., Navasa M, et al. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation. 2002. 74:1381–6.